JointHealth™ express   July 26, 2007

On June 27, 2007, the Common Drug Review (CDR) recommended that provincial drug plans pay for adalimumab (Humira®) for use in the treatment of ankylosing spondylitis (a form of inflammatory arthritis) for people without private insurance coverage. Click here to read the full Common Drug Review recommendation.

This announcement is good news for Canadians living with ankylosing spondylitis that have not responded to non-steroidal anti-inflammatory drugs (or "NSAIDs") such as naproxen, diclofenac, ibuprofen.

Adalimumab is a biologic response modifier (also known as a "TNF-blocker") targeting the TNF-alpha molecule and proved effective at reducing inflammation in the entire spine, the sacroiliac joints, as well as the peripheral joints such as in the fingers and larger joints such as the knees.

To learn if adalimumab may be helpful to you, speak to your rheumatologist or other health care provider helping you to manage your disease.